IGI Logo

Below are Quote on Gland Pharma - 4QFY21 by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd   

Gland pharma limited reported total revenue from operations at ₹887 crores up by 40% YoY from ₹ 635 crores in Q4FY20. Export core market revenue up by 29% to ₹619.3 crores while domestic market has reported growth of 15% at ₹124.8 crores. EBITDA for the quarter at ₹374.9 crores up by 31% as compared to Q4FY20. Company reported an EBITDA margin of 40% down by 200 Bps as compared to 42% of Q4FY20.

Profit after tax for the quarter at ₹260.4 crores in Q4FY21 as compared to 194.8₹ crores up by 34% in Q4FY20. Company reported profit after tax margins of 28% which is also down by 100 bps. 

Gland Pharma limited reported a good set of numbers in Q4FY21, Company has reported good revenue growth in export as well as Domestic market, company is getting several benefits of Covid-19 as company is manufacturing covid 19 related products and selling them in India. Company margins got some hit and are below the market expectations, Profit after tax margins are down by 100bps to 28%. We have a positive outlook towards Gland Pharma limited.

Above views are of the author and not of the website kindly read disclaimer